HIGHLIGHTS
- who: Dashan Ai from the This study was a single-arm phase II clinical trial (NCT02916511), which was initiated in , and finished in , at Fudan University Shanghai Cancer CenterThe protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Center. Eligibility have published the Article: Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9), in the Journal: (JOURNAL)
- what: Compared with the ESO-Shanghai 8 study, the survival results of this study showed a significant improvement in the 2-year local control . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.